Insilico Medicine, a global leader in AI-powered drug discovery, has announced a multi-year research and development collaboration with Servier, the independent international pharmaceutical company. The alliance aims to tackle some of oncology’s toughest targets using Insilico’s proprietary AI platform, Pharma.AI.
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments. The company will lead AI-driven discovery and development of drug candidates, while Servier will share development costs and spearhead clinical validation and commercialization.
“This collaboration underscores Servier’s commitment to applying cutting-edge technologies to address unmet medical needs for the benefit of patients and reflects our confidence in Insilico’s internally developed and validated AI platform,” said Christophe Thurieau, Executive Director of Research at Servier.
Alex Zhavoronkov, founder, CEO, and CBO of Insilico, added, “I am excited to see the collaboration—it is yet another strong acknowledgment of our AI capabilities and R&D expertise. As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development.”
Insilico brings deep experience in AI-driven oncology drug discovery. Its robust pipeline includes potential best-in-class therapies such as the pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412, both in global Phase I trials. Four additional oncology programs have been fully or partially out-licensed, with Phase I studies underway.
The company’s AI and automation approach has accelerated early-stage drug development dramatically. While traditional preclinical discovery typically takes 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, averaging just 12 to 18 months per program—and requiring only 60 to 200 molecules synthesized and tested per project.
